Hester Biosciences Q2 FY26 results: Standalone PAT down 23 percent

Revenue declinedProfit growth above 25%Results restatedResults View source PDF Explain this filing

HESTERBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.4%Reaction day

₹1635.00

prior close

₹1692.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%+2.4% vs market

Pharmaceuticals peers, median of 157sector+0.8%+2.6% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-2.1

15m

-1.9

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.4+0.9+2.4+0.8+2.6

Next day

+4.7+0.8+3.9+0.5+4.2

+3.1+0.7+2.3+0.4+2.7

+1.0+1.3-0.4+0.4+0.5

+2.8+0.5+2.2-0.1+2.9

+3.9+0.4+3.6-0.6+4.5

+1.7-1.5+3.1-1.2+2.8

15d

+0.3-2.4+2.8-1.8+2.1

-2.6-4.4+1.8-2.6-0.1

-5.8-7.2+1.4-5.4-0.5

-4.6-5.0+0.4-6.0+1.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q2 and H1 FY26 results. Standalone Q2 revenue fell 12 percent to INR 645.79M and PAT dropped 23 percent to INR 72.09M. H1 revenue declined 13 percent to INR 1,280.69M with PAT down 15 percent to INR 150.47M. Poultry Healthcare grew 18 percent in Q2 but Animal Healthcare declined 50 percent due to delays in PPR and Lumpy Skin Disease government programmes. Consolidated H1 PAT surged 99 percent to INR 316.27M, boosted by forex gains on Tanzanian Shilling appreciation.

Likely market impact

Mixed results: standalone weakness from delayed government orders offset by strong consolidated growth and forex gains; recovery expected in H2 FY26.